clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Ureteral Obstruction D014517 10 associated lipids
Hemophilia A D006467 10 associated lipids
Gastroesophageal Reflux D005764 10 associated lipids
Dyspnea D004417 10 associated lipids
Hearing Disorders D006311 10 associated lipids
Neuromuscular Diseases D009468 10 associated lipids
Osteomyelitis D010019 10 associated lipids
Pancreatitis D010195 10 associated lipids
Urethritis D014526 9 associated lipids
Urination Disorders D014555 9 associated lipids
Sinusitis D012852 9 associated lipids
Bacteremia D016470 9 associated lipids
AIDS-Related Opportunistic Infections D017088 9 associated lipids
Periodontal Pocket D010514 9 associated lipids
Obstetric Labor, Premature D007752 9 associated lipids
Otitis Media with Effusion D010034 9 associated lipids
Cross Infection D003428 9 associated lipids
Rhabdomyolysis D012206 9 associated lipids
Leprosy D007918 8 associated lipids
Fistula D005402 8 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Fischbach L and Evans EL Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. 2007 Aliment. Pharmacol. Ther. pmid:17635369
Thijs JC et al. Short report: clarithromycin, an alternative to metronidazole in the triple therapy of Helicobacter pylori infection. 1994 Aliment. Pharmacol. Ther. pmid:8186339
Adachi K et al. Efficacy of ecabet sodium for Helicobacter pylori eradication triple therapy in comparison with a lansoprazole-based regimen. 2001 Aliment. Pharmacol. Ther. pmid:11472321
Sierra F et al. Pilot study: miscellaneous therapy is highly successful for Helicobacter pylori eradication. 2013 Aliment. Pharmacol. Ther. pmid:23656465
Kondo Y et al. Helicobacter pylori eradication decreases blood neutrophil and monocyte counts. 2004 Aliment. Pharmacol. Ther. pmid:15298609
Gschwantler M et al. Famotidine versus omeprazole in combination with clarithromycin and metronidazole for eradication of Helicobacter pylori--a randomized, controlled trial. 1999 Aliment. Pharmacol. Ther. pmid:10468682
Paré P et al. Comparison of ranitidine bismuth citrate plus clarithromycin with omeprazole plus clarithromycin for the eradication of Helicobacter pylori. 1999 Aliment. Pharmacol. Ther. pmid:10468683
Di Mario F et al. Bovine lactoferrin for Helicobacter pylori eradication: an open, randomized, multicentre study. 2006 Aliment. Pharmacol. Ther. pmid:16611285
Madisch A et al. Healing of lymphocytic gastritis after Helicobacter pylori eradication therapy--a randomized, double-blind, placebo-controlled multicentre trial. 2006 Aliment. Pharmacol. Ther. pmid:16441467
Borody TJ et al. Efficacy and safety of rifabutin-containing 'rescue therapy' for resistant Helicobacter pylori infection. 2006 Aliment. Pharmacol. Ther. pmid:16441468
Sung JJ et al. One-week use of ranitidine bismuth citrate, amoxycillin and clarithromycin for the treatment of Helicobacter pylori-related duodenal ulcer. 1998 Aliment. Pharmacol. Ther. pmid:9726384
Pazzi P et al. Short-term low-dose pantoprazole-based triple therapy for cure of Helicobacter pylori infection in duodenal ulcer patients. 1998 Aliment. Pharmacol. Ther. pmid:9726385
Shokri-Shirvani J et al. Letter: global emergence of Helicobacter pylori antibiotic resistance - unanswered questions. 2016 Aliment. Pharmacol. Ther. pmid:27137738
Cammarota G et al. One-week therapy for Helicobacter pylori eradication: ranitidine bismuth citrate plus medium-dose clarithromycin and either tinidazole or amoxycillin. 1998 Aliment. Pharmacol. Ther. pmid:9678813
Kashimura H et al. Polaprezinc, a mucosal protective agent, in combination with lansoprazole, amoxycillin and clarithromycin increases the cure rate of Helicobacter pylori infection. 1999 Aliment. Pharmacol. Ther. pmid:10215732
Rinaldi V et al. The management of failed dual or triple therapy for Helicobacter pylori eradication. 1997 Aliment. Pharmacol. Ther. pmid:9354202
Peterson WL et al. Ranitidine bismuth citrate plus clarithromycin is effective for healing duodenal ulcers, eradicating H. pylori and reducing ulcer recurrence. RBC H. pylori Study Group. 1996 Aliment. Pharmacol. Ther. pmid:8791947
Delchier JC et al. Omeprazole-amoxycillin versus omeprazole-amoxycillin-clarithromycin in the eradication of Helicobacter pylori. 1996 Aliment. Pharmacol. Ther. pmid:8791948
Gisbert JP et al. Fourth-line rescue therapy with rifabutin in patients with three Helicobacter pylori eradication failures. 2012 Aliment. Pharmacol. Ther. pmid:22372560
Laine L et al. Randomized comparison of differing periods of twice-a-day triple therapy for the eradication of Helicobacter pylori. 1996 Aliment. Pharmacol. Ther. pmid:8971306